31
October 2024
Iconic
Labs PLC
("Iconic" or the "Company")
Full
Year Results for the Year ended 30 June 2024
Iconic Labs PLC (LSE: ICON),
today announces its audited financial results for the year ended 30
June 2024.
Copies of the Annual Report and
Accounts for the year ended 30 June 2024 will shortly be sent to
shareholders and available on the Company's website:
https://www.iconiclabs.co.uk/documents/.
Period Highlights
· Prospectus published to provide the Company with the ability
to issue further Ordinary Shares under the Prospectus Regulation
Rules
· Signed non-binding heads of terms with the owners of ITS
Holdings 2023 Ltd ("ITS 2023"), the holding vehicle of the entire
issued share capital of In the Style Fashion Ltd ("ITSFL"), in
connection with potential purchase of ITS 2023 (although subsequently resolved instead for the Company to
acquire ITSFL directly from ITS 2023)
· Victor Humberdot and Béla Lendvai-Lintner appointed as
Non-executive Directors
Financial Highlights
· Profit of £418,948
(FY 23: £4,558,623) due to write back of
trade creditors in the year
· Revenue of £Nil (FY 23: £Nil)
· Total assets held as of 30 June 2024 £139,340 (FY 23:
£50,244)
· Group liabilities of £2,857,383 (FY 23: £3,900,141)
John Farquharson, Interim Chief
Executive Officer of Iconic Labs, commented:
"Since announcing the heads of
terms to acquire ITFSL, the management team has continued to
advance the acquisition process, with the current intention to
complete the transaction before the end of the calendar year. We
look forward to providing updates in due course, which will
culminate in the publication of a prospectus if
successful."
For any further information or enquiries please
contact:
Iconic Labs
John Farquharson, Interim
Chief Executive Officer
|
via Yellow Jersey PR
|
Novum Securities Limited
David Coffman / Daniel
Harris
|
Tel: +44 (0) 20 7399
9400
|
Yellow Jersey PR
Charles
Goodwin
Annabelle Wills
Bessie Elliot
|
Tel: +44 (0) 20 3004
9512
iconic@yellowjerseypr.com
|
CHIEF EXECUTIVE OFFICER'S REPORT
I am pleased to present the
audited accounts of Iconic Labs PLC and its subsidiaries (together,
"Iconic" or the "Company") for the twelve months ended 30 June
2024.
Strategic Overview
Historically, Iconic has been a
media and technology business focused on developing ventures and
identifying acquisitions in the online media, artificial
intelligence, and big data sectors. Our sole asset during this
period was Gay Star News ("GSN"), an online media platform
dedicated to the LGBTQ+ community. GSN continues to be part of our
portfolio, championing diversity and inclusion in the digital media
space.
Following our successful exit from
administration and completion of all Company Voluntary Arrangement
("CVA") requirements on 21 September 2023, we initially intended to
develop a strategic advisory services business. This venture aimed
to provide fee-based services to technology companies in our core
sectors, advising on growth strategy, product development, social
media, marketing, and capital raising. However, unfavourable market
conditions led us to reassess this strategy. Recognising the need
for a more viable path forward, we redirected our efforts toward
identifying a suitable acquisition target that would align with our
long-term objectives.
Proposed Acquisition of In The Style Fashion
Limited
After an extensive review of
potential targets and following the suspension of our shares on 29
February 2024, on 11 March 2024 Iconic entered into non-binding
heads of terms with the sellers of ITS Holdings 2023 Ltd "(ITS
2023") the parent company of In The Style Fashion Limited
("ITSFL"), a leading online fashion retailer
Founded in 2013, ITSFL is a
dynamic e-commerce apparel brand with a loyal and growing customer
base of predominantly women aged 16 to 35. The company has carved
out a unique position in the market through its innovative
influencer collaboration model. By partnering with influencers who
have high engagement on social media platforms, ITSFL co-creates
fashion collections that resonate deeply with its target
audience.
We are working with our advisers
to undertake the due diligence necessary to complete the proposed
acquisition. As the transaction will constitute a reverse takeover
under the Listing Rules, our advisers are assisting us with the
process of readmission to the Official List and to trading on the
Main Market of the London Stock Exchange ("Readmission"). As a
result of the due diligence to date, it is now proposed that Iconic
will acquire ITSFL directly from ITS 2023 and will not acquire ITS
2023.
Looking Ahead
The coming year promises to be an
exciting chapter in Iconic's evolution. The completion of the
proposed ITSFL acquisition will be a priority, and we are committed
to realising the full potential of the business. Our focus will be
on leveraging synergies, driving growth, and delivering sustainable
shareholder returns.
On behalf of the Board, I would
like to express my gratitude to our shareholders for their
continued support and patience during this transformative period. I
would also like to thank our stakeholders for their dedication and
trust in our vision.
We look forward to updating you on
our progress in the months ahead.
John Farquharson
Interim Chief Executive Officer
Date: 30 October 2024
STRATEGIC REPORT
INTRODUCTION
This is the eighth set of
financial statements prepared by Iconic. This Strategic Report
should also be read in conjunction with the Chief Executive
Officer's Report.
Principal Activities
Iconic has entered into non-binding heads of terms with the sellers
of ITS Holdings 2023 Ltd, the parent company of In The Style
Fashion Limited, a leading online fashion retailer
Iconic's sole asset is Gay Star
News ("GSN"), an online media platform dedicated to the LGBTQ+
community.
PRINCIPAL RISKS AND
UNCERTAINTIES
The following risks are considered by the Board to be the most significant
to the business:
Reverse Takeover (RTO) Target Risk
Iconic has identified and
announced its target for a proposed RTO, however there is a risk
that the RTO will not complete. The Company continues to work with
its advisers to progress the legal and financial due diligence to
enable the RTO to proceed and will provide further updates in due
course.
Going Concern Risk
If the proposed RTO is not
successful and an alternative target is not found within a short
period of time, there is a risk that further funding will not be
available from the Financing Facility with EHGOSF, and that whilst
the on-going running cost of the Group is expected to be low, the
Group may not be able to meet its liabilities as they fall
due.
Revenue, Profitability and Funding Risk
Iconic currently only has one
asset, GSN, which is not cash-generative and otherwise currently
generates no revenues including from consultancy. The Company has
therefore been reliant upon the Financing Facility with EHGOSF for
its main source of working capital.
The Financing Facility is subject
to a number of conditions ("Conditions") including in
particular:
· The
shares of Iconic trade on the Main Market of the London Stock
Exchange;
·
The closing market price of the Shares for each
of the ten consecutive trading days falling immediately prior to
the relevant closing date must be at least higher than 150% of the
nominal value of Iconic's shares;
·
The average daily value traded of Iconic's shares
(excluding 5% of the data points from the top and excluding 5% of
the data points from the bottom of the data set) for the 20 trading
days immediately prior to the applicable closing date must be at
least £10,000;
·
From the fifth drawdown tranche onwards, Iconic
having published a Prospectus;
· No
binding commitment has been entered into by Iconic pursuant to
which a change of control in Iconic would occur;
·
No occurrence that constitutes an event of
default having occurred and is continuing;
·
The Board having the required
authority;
(1) For the allotment and issue of
at least 200% of such number of Shares as would be required upon
conversion of all outstanding Notes together with the Notes to be
issued pursuant to the relevant drawdown notice calculated by
dividing the aggregate principal amount of all such Notes by the
Closing VWAP as of the date of such drawdown notice; and
(2) To deviate from the
Shareholders' pre-emption and/or preferential subscription right
(as applicable) with respect to such number of Shares;
and
·
No payment is due by the
Company to EHGOSF (or any of its Affiliates) and no delivery of
Shares (or certificates evidencing such Shares) resulting from a
conversion of Notes or exercise of any Warrants by EHGOSF (or any
of its Affiliates) is outstanding.
The Company has secured short-term
funding from EHGOSF and the seller of ITSFL to allow it to pursue
the RTO which it is using to pay its low running costs and
advisers to progress the legal and financial due
diligence.
In the event that the RTO is not
successful, it is possible that some of these conditions will not
be met. As a result, if any such condition is not met, the Company
may not be in a position to further drawdown on the Financing
Facility. Although the Directors would endeavour to pursue certain
options to mitigate the consequence of such breach there is no
certainty that any such options could be achieved either in part or
at all. In such an event the Company would need to wind down its
operations, realise any assets and may enter administration, if and
to the extent there are creditors of the Company who cannot be
paid. In such an event, the Company would no longer manage the
affairs of the Company or the realisation of its assets. As a
result of either winding down the business or entering into
administration, the Ordinary Shares would be cancelled from the
Official List and Shareholders may receive little or no value for
their Ordinary Shares.
Dilution and Pricing Risk
If EHGOSF exercises its full
rights under the Financing Facility for conversion of Loan Notes
and Warrants into Shares, this could result in a significant
holding in the Company by EHGOSF. However, EHGOSF's strategy is
generally to sell shares in the market as soon as practicable
following the exercise of such rights and in any event under the
Financing Facility, inter alia, EHGOSF cannot hold more than 29.9%
of the Company. Accordingly, there is a risk that should the
Company seek to drawdown under the Loan Notes and EHGOSF thereafter
exercise and sell Shares in significant amounts over a lengthy
period, this could have a material negative impact on the price of
the Shares.
Potential Unrecorded Legacy Liabilities
As evidenced by the administration
and disputes involving various key parties, there were significant
legacy issues that predated management's arrival. Following the
exit from administration and the entering into of confidential
settlement agreements with various parties, the Directors consider
that it is unlikely that there are any material unknown liabilities
of Iconic, however there is the potential for unknown creditors to
emerge which would increase the liabilities of the
Company.
Financial Risk Management
The Board monitors the internal
risk management function across Iconic and advises on all relevant
risk issues. There is regular communication with internal
departments, external advisors and regulators. Iconic's policies on
financial instruments and the risks pertaining to those instruments
are set out in the accounting policies in note 1 of the financial
statements.
Key
Performance Indicators
The business is currently focused
on the areas of cash management and operating results.
Iconic has identified the
following key performance indicators which the Directors will use
to measure success against the business plan following the reverse
takeover:
· Gross revenue growth
· EBITDA growth
· Market value
FUTURE DEVELOPMENT AND
STRATEGY
Company Strategy
As set in the August
2023 Prospectus, the Company had intended to resume its
historical revenue-generating offering by identifying companies in
the online media, artificial intelligence, and big data gathering,
processing and analysis sectors with which it could enter into
advisory services contracts. At the time, it was thought that such
advisory services could provide the Company with short-term
revenues and news flow while it continued to search for a suitable
acquisition target.
However, given the limited number
of personnel working with the Company, the time commitment needed
to properly provide advisory services to prospective clients, and
current unfavourable market conditions, the Company decided that
this short-term strategy was no longer viable. As such it decided
to cease this strategy in favour of focusing all of its time,
resources, and energy on acquiring a suitable company through an
RTO to generate long-term growth and value for its
shareholders.
Going Concern
The Board's assessment of going
concern and the key considerations are set out in our Corporate
Governance Report.
Capital Structure
Details of the Ordinary Shares of
the Company are shown in note 11. On 13
February 2024 the Company's Ordinary Shares of £0.1 were subdivided
into Ordinary Shares of £0.0001 each and Deferred Shares of £0.999
each. The Company also has a class of
Deferred Shares of £0.00249 per share. No shares are entitled to a
fixed income. Each holder of Ordinary Shares is entitled to receive
Iconic's Annual Report and audited financial statements, to attend
and speak or appoint proxies and to exercise voting rights at
Iconic's general meetings.
The Company's Articles of
Association (the "Articles") do not have any specific
restrictions on the transfer of shares or restrictions on voting
rights, and there are no limitations on holding such shares. Other
than the obligations contained in the Financing Facility, the
Settlement Deed, and the CVA, the Directors are not aware of any
agreement between Iconic shareholders that may result in
restrictions on the transfer of securities or on voting
rights.
No person has any special rights
of control over Iconic's share capital and all issued shares are
fully paid.
The appointment and replacement of
Directors and the powers of the Directors are governed by the
Articles, the Quoted Companies Alliance Corporate Governance Code,
the Companies Act 2006 and related legislation. The powers of the
Directors are described in the Corporate Governance
Report.
Environmental Issues
As far as the Directors are aware,
Iconic's business activities do not cause a direct and
disproportionate adverse effect on the environment.
Employee Matters
As of 30 June 2024, and continuing
through the fourth quarter of 2024, Iconic did/does not have any
employees and its management is being conducted primarily by John
Farquharson. Therefore, the Directors believe that this
information is not relevant for the year ended 30 June 2024 and
have not disclosed any information to that effect.
Social, Community and Human Rights Issues
Iconic seeks to achieve the
highest ethical standards and behaviours in conducting its
business, with integrity, openness, diversity and inclusiveness
being a priority.
Section 172 Statement
Section 172 of the Companies Act
2006 requires directors to take into consideration the interests of
stakeholders and other matters in their decision making. The
Directors continue to have regard to the interests of Iconic's
personnel and other stakeholders, the impact of its activities on
the community, the environment and its reputation for good business
conduct, when making decisions. In this context, acting in good
faith and fairly, the directors consider what is most likely to
promote the success of Iconic for its members in the long term. We
explain in this annual report, and below, how the board engages
with stakeholders.
Relations with key stakeholders
such as employees, shareholders and suppliers are considered in
more detail in the Corporate Governance Report.
The Directors are aware of their
responsibilities to promote the success of Iconic in accordance
with section 172 of the Companies Act 2006. To ensure Iconic was
operating in line with good corporate practice, all Directors
received refresher training on the scope and application of section
172 in writing. This encouraged the Board to reflect on how Iconic
engages with its stakeholders and opportunities for enhancement in
the future. A section 172 notice has been included with the Board
papers since this date. As required, Iconic's Company Secretary
will provide support to the Board to help ensure that sufficient
consideration is given to issues relating to the matters set out in
s172(1)(a)-(f).
The Board regularly reviews
Iconic's principal stakeholders and how It engages with them. This
is achieved through information provided by management and by
direct engagement with stakeholders themselves. We aim to work
responsibly with our stakeholders, including suppliers. The Board
has recently reviewed its anti-corruption and anti-bribery, equal
opportunities and whistleblowing policies.
The key events and Board decisions
made in the year are set out below:
8 August 2023 - Publication of
Prospectus.
25 August 2023 - AGM held and
Ordinary Shares Consolidated.
15 September 2023 - 83,256
Ordinary Shares issued to all creditors under the CVA.
12 October 2023 - Documents
terminating CVA filed with and accepted by Companies
House.
13 February 2024 - AGM held and
Ordinary Shares sub-divided and converted.
29 February 2024 - Suspension of
trading in the shares and RNS confirmation that Iconic was in
discussions regarding a potential acquisition.
John Farquharson
Director
Date: 30 October 2024
CONSOLIDATED STATEMENT OF COMPREHENSIVE
INCOME
FOR
THE YEAR ENDED 30 JUNE 2024
|
|
|
Notes
|
Year
ended
30
June
2024
£
|
|
Year
ended
30
June
2023
(restated)
£
|
|
|
|
|
|
|
|
Revenue
|
|
|
|
-
|
|
-
|
|
|
|
|
|
Gross profit
|
|
-
|
|
-
|
|
|
|
|
|
Administrative
expenses
|
3
|
418,948
|
|
4,558,579
|
Other operating
income
|
|
-
|
|
44
|
|
|
|
|
|
Operating Profit
|
|
418,948
|
|
4,558,623
|
|
|
|
|
|
Profit before
taxation
|
|
418,948
|
|
4,558,623
|
|
|
|
|
|
Income tax expense
|
5
|
-
|
|
-
|
|
|
|
|
|
Profit for the
year
|
|
418,948
|
|
4,558,623
|
|
|
|
|
|
Total comprehensive profit for the
year
|
|
418,948
|
|
4,558,623
|
|
|
|
|
|
Earnings per share attributable to
equity shareholders of the Company
|
6
|
|
|
|
- Basic earnings per share
- Diluted earnings per share
|
|
0.05
0.01
|
|
0.00
0.00
|
|
|
|
|
|
The profit for the year and total
comprehensive profit for the year are wholly attributable to the
equity holders of the parent.
The results above have been
derived from continuing operations.
|
CONSOLIDATED STATEMENT OF FINANCIAL
POSITION
AS
AT 30 JUNE 2024
|
|
|
|
|
|
|
|
Notes
|
|
30
June
2024
|
|
30
June
2023
(restated)
|
|
|
|
|
|
|
|
|
|
£
|
|
£
|
|
Assets
Non-current
assets
|
|
|
|
|
|
|
|
|
|
|
|
Intangible
assets
|
|
|
|
|
|
7
|
|
1
|
|
1
|
|
Total non-current
assets
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
|
|
|
Trade and other
receivables
|
|
|
|
|
|
9
|
|
10,030
|
|
-
|
|
Cash and cash
equivalents
|
|
|
|
|
|
10
|
|
129,309
|
|
50,243
|
|
|
|
|
|
|
|
|
|
139,339
|
|
50,243
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
|
|
|
|
|
139,340
|
|
50,244
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
Share capital
|
|
|
|
|
|
11
|
|
5,192,602
|
|
4,539,523
|
|
Share premium
|
|
|
|
|
|
12
|
|
8,401,588
|
|
8,341,761
|
|
Accumulated
losses
|
|
|
|
|
|
12
|
|
(16,312,233)
|
|
(16,731,181)
|
|
|
|
|
|
|
|
|
|
(2,718,043)
|
|
(3,849,897)
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
|
|
|
Trade and other
payables
|
|
|
|
|
|
13
|
|
210,604
|
|
1,750,141
|
|
Loans and
borrowings
|
|
|
|
|
|
14
|
|
2,646,779
|
|
2,150,000
|
|
|
|
|
|
|
|
|
|
2,857,383
|
|
3,900,141
|
|
Total
liabilities
|
|
|
|
|
|
|
|
2,857,383
|
|
3,900,141
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity and
liabilities
|
|
|
|
|
|
|
|
139,340
|
|
50,244
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR
THE YEAR ENDED 30 JUNE 2024
|
Share
capital
£
|
Share
premium
£
|
Accumulated
losses
£
|
Total
Equity
£
|
|
|
|
|
|
Balance at 30 June
2022
|
4,450,506
|
7,900,778
|
(21,289,804)
|
(8,938,520)
|
|
|
|
|
|
Profit for the
period
|
-
|
-
|
4,768,623
|
4,768,623
|
Total comprehensive profit for the
period
|
-
|
-
|
4,768,623
|
4,768,623
|
Transactions with
owners:
|
|
|
|
|
Issue of shares
|
89,017
|
440,983
|
|
530,000
|
Total contribution by and
distribution to owners
|
89,017
|
440,983
|
|
530,000
|
|
|
|
|
|
Balance at 30 June
2023 as previously
presented
|
4,539,523
|
8,341,761
|
(16,521,181)
|
(3,639,897)
|
Prior period adjustment (note
16)
|
-
|
-
|
(210,000)
|
(210,000)
|
Balance at 30 June
2023 as restated
|
4,539,523
|
8,341,761
|
(16,731,181)
|
(3,849,897)
|
|
|
|
|
|
Profit for the
year
|
-
|
-
|
418,948
|
418,948
|
Total comprehensive profit for the
year
|
-
|
-
|
418,948
|
418,948
|
Transactions with
owners:
|
|
|
|
|
Issue of shares
|
653,079
|
59,827
|
-
|
712,906
|
Total contribution by and
distribution to owners
|
653,079
|
59,827
|
-
|
712,906
|
|
|
|
|
|
Balance at 30 June
2024
|
5,192,602
|
8,401,588
|
(16,312,233)
|
(2,718,043)
|
Share premium includes premiums on
issue of share capital, less associated issue costs.
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR
THE YEAR ENDED 30 JUNE 2024
|
|
|
|
|
Notes
|
|
Year ended
30 June
2024
|
|
Year ended
30 June
2023
(restated)
|
|
|
|
|
|
£
|
|
£
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
Total comprehensive profit for the
year
|
|
|
|
|
418,948
|
|
4,558,623
|
Costs relating to EHGOSF
facility
|
|
|
|
|
310,006
|
|
-
|
Net write back of trade
creditors
|
|
|
|
|
(1,509,225)
|
|
(6,117,482)
|
Net write back of loan
notes
|
|
|
|
|
-
|
|
(915,000)
|
|
|
|
|
|
(780,271)
|
|
(2,473,859)
|
|
|
|
|
|
|
|
|
Increase in trade and other
receivables
|
|
|
9
|
|
(10,030)
|
|
-
|
(Increase)/decrease in trade and
other payables
|
|
|
13
|
|
(12,412)
|
|
1,554,097
|
Net cash used in operating activities
|
|
|
(802,713)
|
|
(919,762)
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
Cash flows from issue for
promissory notes
|
|
|
14
|
|
631,779
|
|
-
|
Cash flows from issue of
convertible loan notes
|
|
|
14
|
|
250,000
|
|
970,000
|
Net cash flows from financing activities
|
|
|
|
|
881,779
|
|
970,000
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents
|
|
|
|
|
79,066
|
|
50,238
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of year
|
|
|
|
|
50,243
|
|
5
|
Cash and cash equivalents at year end
|
|
|
10
|
|
129,309
|
|
50,243
|
|
|
|
|
|
|
|
|
|
|
|
|
COMPANY STATEMENT OF
FINANCIAL POSITION
AS AT 30 JUNE 2024
|
|
|
Notes
|
|
30
June
2024
|
|
30
June
2023
(restated)
|
|
|
|
£
|
|
£
|
Non-current
assets
|
|
|
|
|
|
Investments
|
8
|
|
1
|
|
1
|
Non-current
assets
|
|
|
1
|
|
1
|
Current assets
|
|
|
|
|
|
Trade and other
receivables
|
9
|
|
10,030
|
|
-
|
Cash and cash
equivalents
|
10
|
|
129,309
|
|
50,243
|
|
|
|
139,339
|
|
50,243
|
|
|
|
|
|
|
Total assets
|
|
|
139,340
|
|
50,244
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
Share capital
|
11
|
|
5,192,602
|
|
4,539,523
|
Share
premium
|
12
|
|
8,401,588
|
|
8,341,761
|
Accumulated
losses
|
12
|
|
(16,312,233)
|
|
(16,731,181)
|
|
|
|
(2,718,043)
|
|
(3,849,897)
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Trade and other
payables
|
13
|
|
210,604
|
|
1,750,141
|
Loans and
borrowings
|
14
|
|
2,646,779
|
|
2,150,000
|
|
|
|
2,857,383
|
|
3,900,141
|
Total
liabilities
|
|
|
2,857,383
|
|
3,900,141
|
|
|
|
|
|
|
Total equity and
liabilities
|
|
|
139,340
|
|
50,244
|
|
|
|
|
|
|
|
|
|
|
The Company's profit and total
comprehensive profit for the year ended 30 June 2024 was
£418,948 (restated 30 June 2023: £4,558,623
profit).
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2024
|
Share
capital
£
|
Share
premium
£
|
Accumulated
losses
£
|
Total
equity
£
|
|
|
|
|
|
Balance at 01 July
2023
|
4,450,506
|
7,900,778
|
(21,289,344)
|
(8,938,060)
|
|
|
|
|
|
Profit for the
period
|
-
|
-
|
4,768,163
|
4,768,163
|
Total comprehensive profit for
period
|
-
|
-
|
4,768,163
|
4,768,163
|
Transactions with
owners
|
|
|
|
|
Issue of shares
|
89,017
|
440,983
|
-
|
530,000
|
Total contributions by and
distributions to owners
|
89,017
|
440,983
|
-
|
530,000
|
|
|
|
|
|
Balance at 30 June
2023 as originally
presented
|
4,559,523
|
8,341,761
|
(16,521,181)
|
(3,639,897)
|
Prior period adjustment (note
16)
|
-
|
-
|
(210,000)
|
(210,000)
|
Balance at 30 June 2023 as
restated
|
4,559,523
|
8,341,761
|
(16,731,181)
|
(3,849,897)
|
|
|
|
|
|
Balance at 01 July
2023
|
4,359,523
|
8,341,761
|
(16,731,181)
|
(3,849,897)
|
Profit for the
year
|
-
|
-
|
418,948
|
418,948
|
Total comprehensive profit for
year
|
-
|
-
|
418,948
|
418,948
|
Transactions with
owners
|
|
|
|
|
Issue of shares
|
653,079
|
59,827
|
-
|
712,906
|
Total contributions by and
distributions to owners
|
653,079
|
59,827
|
-
|
712,906
|
|
|
|
|
|
Balance at 30 June
2024
|
5,192,602
|
8,401,588
|
(16,312,233)
|
(2,718,043)
|
Share premium includes premiums on
issue of share capital, less associated issue costs.
1. Accounting Policies
Company information
The principal activity of ("the
Company") is that of a holding company. The Company is a public
company limited by shares registered in England & Wales. The
registered office of the Company is 7 Bell Yard, London, WC2A 2JR.
The Company registration number is 10197256.
Basis of preparation
These financial statements have
been prepared in accordance with applicable law and UK Adopted
International Accounting Standards ("UK Adopted IASs").
These consolidated financial
statements are presented in Pounds Sterling ('GBP'), which is
considered by the directors to be the functional and presentation
currency.
The Company's individual statement
of comprehensive income has been omitted from the Group's annual
financial statements having taken advantage of the exemption not to
disclose under Section 408(3) of the Companies Act 2006.
Going concern
As noted in the Corporate
Governance Report, the Directors have carefully considered the
financial position of Iconic in light of progress during the twelve
months ended 30 June 2024. The Directors have identified and
announced a target for a proposed RTO transaction and have secured
short term funding to progress the financial and legal due
diligence, however there is a risk that the transaction may not
complete. If the proposed RTO is not successful and an
alternative target is not found within a short period of time,
there is a risk that further funding will not be available from the
Financing Facility with EHGOSF, and that whilst the on-going
running costs of the Group are expected to be low, the Group may
not be able to meet its liabilities as they fall
due.
In such an event the Group would
need to wind down its operations, realise any assets and may enter
administration, if and to the extent there are creditors of the
Company who cannot be paid. In such an event, the Group would no
longer manage its affairs or the realisation of its assets. As a
result of either winding down the business or entering into
administration, the Ordinary Shares would be cancelled from the
Official List and Shareholders may receive little or no value for
their Ordinary Shares.
On this basis, there is a material
uncertainty related to events or conditions that may cast
significant doubt on the Group's ability to continue as a going
concern and that it may therefore be unable to realise its assets
and discharge its liabilities in the normal course of business. The
Directors believe it remains appropriate to prepare the financial
statements on a going concern basis
Basis of consolidation
The Group financial statements
consolidate those of the parent company and all of its
subsidiaries. Subsidiaries are entities controlled by the Group.
The parent company controls a subsidiary if it has power over the
investee to significantly direct the activities, exposure, or
rights, to variable returns from its involvement with the investee,
and the ability to use its power over the investee to affect the
amount of the investors' returns. The financial statements of
subsidiaries are included in the consolidated financial statements
from the date that control commences until the date that control
ceases.
The results of subsidiaries
acquired or disposed in the period are included in the consolidated
income statement from the effective date of acquisition or up to
the effective date of disposal, as appropriate. All intra-group
transactions, balances, income and expenses are eliminated on
consolidation.
The results and net assets of
subsidiaries whose accounts are denominated in foreign currencies
are retranslated into Sterling at average rates and year-end rates
respectively.
Where the Group has the power to
participate in (but not control) the financial and operating policy
decisions of another entity, it is classified as an associate.
Associates are initially recognised in the consolidated statement
of financial position at cost. Subsequently associates are
accounted for using the equity method, where the Group's share of
post-acquisition profits and losses and other comprehensive income
is recognised in the consolidated statement of profit and loss and
other comprehensive income (except for losses in excess of the
Group's investment in the associate unless there is an obligation
to make good those losses).
Taxation
The tax expense represents the sum
of the tax currently payable and deferred tax. The tax currently
payable is based on taxable profit for the year. Taxable profit
differs from net profit as reported in the income statement because
it excludes items of income or expense that are taxable or
deductible in other years and it further excludes items that are
never taxable or deductible.
Deferred tax is the tax expected
to be payable or recoverable on temporary differences between the
carrying amounts of assets and liabilities in the financial
statements and the corresponding tax bases used in the computation
of taxable profit, and is accounted for using the balance sheet
liability method. Deferred tax liabilities are generally recognised
for all taxable temporary differences and deferred tax assets are
recognised to the extent that it is probable that taxable profits
will be available against which deductible temporary differences
can be utilised. Such assets and liabilities are not recognised if
the temporary difference arises from goodwill or from the initial
recognition (other than in a business combination) of other assets
and liabilities in a transaction that affects neither the tax
profit nor the accounting profit.
Deferred tax liabilities are
recognised for taxable temporary differences arising on investments
in subsidiaries and associates, and interests in joint ventures,
except where the Group is able to control the reversal of the
temporary difference and it is probable that the temporary
difference will not reverse in the foreseeable future.
The carrying amount of deferred
tax assets is reviewed at each reporting date and reduced to the
extent that it is no longer probable that sufficient taxable
profits will be available to allow all or part of the asset to be
recovered.
Deferred tax is measured on an
undiscounted basis using the tax rates that are expected to apply
in the period when the liability is settled or the asset is
realised. Deferred tax is charged or credited in the income
statement, except when it relates to items charged or credited
directly to equity, in which case the deferred tax is also dealt
with in equity.
Intangible fixed assets
Intangible assets comprise
capitalised computer software which are initially recognised at
cost.
Amortisation is provided so as to
write off their carrying value over their expected useful economic
lives. It is provided at the following rates:
Computer Software
|
33% straight line basis
|
Intangible assets also comprise
intellectual property which is initially measured at cost. The
useful economic life of the asset is considered to be such that any
amortisation charge would be immaterial to the financial
statements. The directors have therefore decided that an annual
impairment review rather than a systematic amortisation is more
appropriate for this asset.
Impairment of non-current assets
At each reporting date the Group
reviews the carrying amounts of its property, plant and equipment
and intangible assets to determine whether there is any indication
that those assets have suffered an impairment loss. If any such
indication exists, the recoverable amount of the asset is estimated
in order to determine the extent of the impairment loss (if
any).
If the recoverable amount of an
asset is estimated to be less than its carrying amount, the
carrying amount of the asset is reduced to its recoverable amount.
An impairment loss is recognised as an expense immediately, unless
the relevant asset is carried at a revalued amount, in which case
the impairment loss is treated as a revaluation
decrease.
Financial assets
Financial assets are recognised
when the Group becomes a party to the contractual provisions of the
financial asset.
Financial assets are derecognised
when the contractual rights to the cash flows from the financial
assets expire, or when the financial asset and substantially all of
the risks and rewards are transferred.
The financial assets of the Group
are initially measured at fair value adjusted for transaction costs
(where applicable).
Financial assets are classified
into the following categories:
-
Amortised cost
- Fair
value through profit or loss (FVTPL)
- Fair
value through other comprehensive income (FVOCI)
The classification is determined
by both:
- The
Group's business model for managing the financial asset
- The
contractual cash flow characteristics of the financial
asset
All income and expenses relating
to financial assets that are recognised in profit or loss are
presented within finance costs and finance income.
Financial assets are measured at
amortised cost if the assets meet the following conditions (and are
not designated as FVTPL):
- They are
held within a business model whose objective is to hold the
financial assets and collect its contractual cash flows
- The
contractual terms of the financial assets give rise to cash flows
that are solely payments of principal and interest on the principal
amount outstanding
After initial recognition, these
are measured at amortised cost using the effective interest method.
Discounting is omitted where its effect is immaterial. The Group's
cash and cash equivalents, trade and other receivables fall into
this category.
An impairment loss in respect of a
financial asset measured at amortised cost is calculated as the
difference between its carrying amount and the present value of the
estimated future cash flows discounted at the asset's original
effective interest rate. Losses are recognised in profit or loss
and reflected in an allowance against trade and other receivables.
When an event occurring after the impairment was recognised causes
the amount of impairment loss to decrease, the decrease in
impairment loss is reversed through profit or loss.
Trade and other receivables
The Group makes use of a
simplified approach in accounting for trade and other receivables
and records the loss allowance as lifetime expected credit losses.
These are the expected shortfalls in contractual cash flows,
considering the potential for default at any point during the life
of the financial instrument. In calculating, the Group uses its
historical experience, external indicators and forward-looking
information to calculate the expected credit losses using a
provision matrix.
The Group assesses impairment of
trade and other receivables on a collective basis.
Cash and cash equivalents
Cash and cash equivalents comprise
cash balances and call deposits. These are initially and
subsequently recorded at fair value.
Financial liabilities
The Group's principal financial
liabilities include trade and other payables, leases and
convertible debt none of which would be classified as fair value
through profit or loss.
Therefore, these financial
liabilities are classified as financial liabilities at amortised
cost, as defined below:
Other financial liabilities
include the following items:
· Borrowings are initially recognised at fair value net of any
transaction costs directly attributable to the issue of the
instrument. Such interest-bearing liabilities are subsequently
measured at amortised cost using the effective interest method,
which ensures that any interest expense over the period to
repayment is at a constant rate on the balance of the liability
carried in the statement of financial position. Interest expense in
this context includes initial transaction costs and premium payable
on redemption, as well as any interest or coupon payable while the
liability is outstanding.
· Trade payables and other short-term monetary liabilities,
which are initially recognised at fair value and subsequently
carried at amortised cost using the effective interest
method.
Convertible loan notes
Convertible loan notes issued by
the Group comprise loan notes that can be converted to ordinary
shares at the option of the holder. Convertible loan notes
are recognised on the balance sheet when the entity becomes a party
to the contractual provisions of the instrument and are measured at
fair value upon initial recognition
Convertible loan notes are
classified as financial liabilities at amortised cost unless they
meet the criteria to be classified and measured at fair value
through profit or loss. Derecognition occurs when the loan notes
are converted to ordinary shares.
Promissory notes
Promissory notes are classified as
financial instruments and recognised on the balance sheet when the
entity becomes a party to the contractual provisions of the
instrument. Upon initial recognition, promissory notes are measured
at fair value, typically the transaction price, plus any directly
attributable transaction costs. If a promissory note is issued with
deferred payment terms or at an interest rate that does not reflect
the market rate, it is initially measured at fair value, determined
by discounting future cash flows at a market rate of
interest.
Promissory notes payable are
classified as financial liabilities at amortised cost unless they
meet the criteria to be classified and measured at fair value
through profit or loss. Promissory notes payable classified at
amortised cost are subsequently measured using the effective
interest rate method, recognising interest expense over the term of
the note. Derecognition occurs when the obligation is discharged,
cancelled, or expired.
Share capital
The Group's ordinary shares are
classified as equity instruments.
Changes to IFRS not yet adopted
As from 1 January 2024, various
amendments to IFRS standards as listed below were issued but have
not been applied in these financial statements. Their adoption is
not expected to have a material effect on the financial statements
of the Company and Group.
The following UK-adopted IFRSs
have been issued but have not been applied in these financial
statements. Their adoption is not expected to have a material
effect on the financial statements:
· Amendments to IFRS 16 Leases: Lease Liability in a Sale and
Leaseback (effective 1 January 2024).
·
Amendments to IAS 1
Presentation of Financial Statements: Classification of Liabilities
as Current or Non-current and Non-current liabilities with
Covenants (effective 1 January 2024).
· Amendments to IAS 7 Statement of Cash Flows and IFRS 7
Financial Instruments: Disclosures: Supplier Finance Arrangements
(effective 1 January 2024).
The following standards and
interpretations to published standards are not yet
effective:
· Amendments to IAS 21: Lack of exchangeability (endorsed -
effective 1 January 2025).
· Amendments to IFRS 9 and IFRS 7: Classification and
Measurement of Financial Instruments (issued - effective 1 January
2026)
· IFRS
18: Presentation and Disclosure in Financial Statements (issued -
effective 1 January 2027)
· Amendments to IFRS 10 and IAS 28: Sale or Contribution of
Assets between an Investor and its Associate or Joint Venture
(deferred).
The Directors anticipate that the
adoption of these standards and interpretations in future periods
will not have an impact on the results and net assets of the
Company and Group.
2. Significant judgements and
key sources of estimation uncertainty
The Group makes certain estimates
and assumptions regarding the future. Estimates and judgements are
continually evaluated based on historical experience and other
factors, including expectations of future events that are believed
to be reasonable under the circumstances. In the future, actual
experience may differ from these estimates and assumptions.
Significant management judgements are as follows:
Legacy
Issues
· Due
to the change in the Board, key management and operations of the
Group that took place in March 2021, it is possible that there are
unrecorded liabilities relating to discontinued activities about
which the Board is unaware. The Board has undertaken, to the extent
possible, a thorough review of the creditor position of the Parent
Company and the Group, with a core focus on the legacy business
operations. Notwithstanding the Board's assessment, there is a
residual risk unforeseen liabilities may arise. However,
due to the publicity around the
new business, shutting down the old one and drawing down on the
EHGOSF facility, a number of claims were made against the company.
While it is important to consider these liabilities in these
accounts the Board has however made a judgment that the risk
of unrecorded actual or contingent liabilities is now
low.
·
The Group's former Board under through its
Cellplan subsidiary was promoting bespoke stem cell medical
insurance and launched a website to market the product. After due
enquiry, the new Board is not aware that any such policies were
issued. There does however remain a residual risk that policies may
have been issued. The Board considers that the incidence and
financial impact is now low.
3.
Profit from
Operations
|
Year ended
30 June
2024
£
|
Year ended
30 June
2023
(restated)
£
|
The loss for the period is stated
after charging:
|
|
|
Auditors' remuneration - audit
services
|
29,000
|
30,000
|
Expenses by
nature:
|
£
|
£
|
Legal and professional
fees
|
646,958
|
802,578
|
Consultancy
fees
|
168,375
|
433,368
|
Other supplies and external
services
|
274,944
|
322,957
|
Total operating
expenses
|
1,090,277
|
1,558,903
|
Creditors written
off
|
(1,509,225)
|
(6,117,482)
|
Total administrative
expenses
|
(418,948)
|
(4,558,579)
|
4.
Staff
Costs
No wages were paid during this year
or the previous year.
Employee Numbers
|
|
|
The average number of staff
employed by the group during the period amounted to:
|
General and
administration
|
4
|
3
|
|
4
|
3
|
Key management personnel compensation
Key management personnel are those
persons having authority and responsibility for planning, directing
and controlling the activities, and are the directors of the
Company.
Remuneration of the directors and
highest paid director is shown in the Remuneration Committee
Report.
5.
Income tax
expense
|
Year ended
30 June 2024
£
|
Year ended
30 June 2023
£
|
|
|
|
Current tax
|
-
|
-
|
Total current tax
|
-
|
-
|
The reason for the difference
between the actual tax charge for the period and the standard rate
of corporation tax in the United Kingdom applied to losses for the
period are as follows:
|
Year ended
30 June 2024
£
|
Year ended
30 June 2023
(restated)
£
|
Profit before taxation
|
418,948
|
4,558,623
|
Tax using the parent company's
domestic tax rate of 25% (2023: 19%)
|
104,737
|
866,138
|
Effects of:
|
|
|
Utilisation of tax losses and other
deductions arising in the period
|
(104,737)
|
(866,138)
|
Total tax charged in the income statement
|
-
|
-
|
The deferred taxation has not been
recognised in these accounts due to the uncertainty over whether
this will be recovered.
6.
Earnings per
share
|
Year ended
30 June 2024
£
|
Year ended
30 June 2023
(restated)
£
|
Basic earnings per share
Numerator
|
|
|
Profit for the year
|
418,948
|
4,558,623
|
Denominator
|
|
|
Weighted average number of ordinary
shares used in basic earnings per share (units)
|
8,784,726
|
46,306,916,660
|
Basic earnings per share
|
0.05
|
0.00
|
Diluted earnings per share
Numerator
|
|
|
Profit for the year
|
418,948
|
4,558,623
|
Denominator
|
|
|
Weighted average number of ordinary
shares used in basic earnings per share (units)
|
8,784,726
|
46,306,916,660
|
Impact of potential dilutive shares
(units)
|
20,150,000
|
19,400,000
|
Adjusted weighted average number of
shares (units)
|
28,934,726
|
46,326,316,660
|
Diluted earnings per
share
|
0.01
|
0.00
|
7.
Intangible
Assets
|
|
|
|
|
Intellectual Property
£
|
Total
£
|
Cost
|
|
|
|
|
Balance at 30 June
2023
|
|
|
21,600
|
21,600
|
Additions
|
|
|
|
|
-
|
-
|
Balance at 30 June
2024
|
|
|
21,600
|
21,600
|
|
|
|
|
|
|
|
|
|
|
Amortisation
|
|
|
|
|
Balance at 30 June
2023
|
|
|
21,599
|
21,599
|
Impairment
|
|
|
-
|
-
|
Balance at 30 June
2024
|
|
|
21,599
|
21,599
|
|
|
|
|
|
|
|
|
|
|
Carrying
amounts
|
|
|
|
|
Balance at 30 June
2024
|
|
|
1
|
1
|
Balance at 30 June
2023
|
|
|
|
1
|
1
|
8.
Investments
Company
|
30 June
2024
£
|
30 June
2023
£
|
Investments in
subsidiaries
|
1
|
1
|
|
|
|
|
1
|
1
|
Subsidiaries as at 30 June 2024:
Entity
|
Registered office
address
|
Country of
incorporation
|
Nature of
business
|
Notes
|
WideCells International
Limited
|
PO Box 4385, 09962594: COMPANIES
HOUSE DEFAULT ADDRESS, Cardiff, CF14 8LH
|
United Kingdom
|
Holding company
|
(c) (d)
|
WideCells Portugal SA
|
Rua Da Casa Branca, 97 Coimbra
3030-109, Portugal
|
Portugal
|
Dormant company
|
(a)
|
WideCells Espana SL
|
Calle Castillo de Fuensaldana, 4,
28232 Las Rozas, Madrid
|
Spain
|
In liquidation
|
(a)
|
CellPlan Limited
|
PO Box 4385, 09962594: COMPANIES
HOUSE DEFAULT ADDRESS, Cardiff, CF14 8LH
|
United Kingdom
|
Dormant company
|
(a) (d)
|
CellPlan International
Lda
|
Edificio Tower Plaza Rotunda Eng,
Edgar Cardoso, no. 23, 11 F, 4400-676 Vila Nova de Gaia,
Portugal
|
Portugal
|
Dormant company
|
(b) (d)
|
Nuuco Media Limited
|
PO Box 4385, 09962594: COMPANIES
HOUSE DEFAULT ADDRESS, Cardiff, CF14 8LH
|
United Kingdom
|
Dormant company
|
(c) (d)
|
Notes: (a) 100%
owned by WideCells International Limited (b) 100%
owned by CellPlan Limited
(c) 100% owned by Iconic Labs plc
(d) Ordinary Shares
Held
9.
Trade and other
receivables
Group
|
|
30 June
2024
£
|
30 June
2023
£
|
Prepayments and accrued
income
|
|
10,030
|
-
|
Total
|
|
10,030
|
-
|
Company
|
|
30 June
2024
£
|
30 June
2023
£
|
Prepayments and accrued
income
|
|
10,030
|
-
|
Total
|
|
10,030
|
-
|
10. Cash and cash
equivalents
Group
|
30 June
2024
£
|
30 June
2023
£
|
Cash at bank available on
demand
|
129,309
|
50,243
|
Total cash and cash
equivalents
|
129,309
|
50,243
|
Company
|
30 June
2024
£
|
30 June
2023
£
|
Cash at bank available on
demand
|
129,309
|
50,243
|
Total cash and cash
equivalents
|
129,309
|
50,243
|
11. Company Share
Capital
|
30 June
2024
|
30 June
2023
|
|
Number
|
£
|
Number
|
£
|
Authorised, allotted and fully paid - classified as
equity
|
|
|
|
|
Ordinary shares of £0.10
each
(2023 - £0.00001 each)
|
11,161,483
|
1,116,148
|
46,306,916,660
|
463,069
|
Deferred shares of £0.00249
each
|
1,637,129,905
|
4,076,454
|
1,637,129,905
|
4,076,454
|
Total
|
1,648,291,388
|
5,192,602
|
47,944,046,565
|
4,539,523
|
At 30 June 2023, the Company had
46,306,916,660 Ordinary shares of £0.00001 in issue and
1,637,129,905 Deferred shares of £0.00249 in issue.
In August 2023, the Company issued
689,655,172 Ordinary shares of £0.00001 for £0.000039 each in
respect of a conversion of loan notes by EHGOSF.
Following the share issue above,
the Company undertook a share consolidation. For every 10,000
£0.0001 Ordinary shares held, the shareholder received 1 Ordinary
share of £0.10. In order to facilitate this consolidation, the
Company had to issue 8,168 Ordinary shares of £0.0001 prior to the
consolidation.
In September 2023, the Company
issued 220,361 Ordinary shares of £0.10 each for £0.23 each,
236,406 were issued for £0.13 each and 271,739 were issued for
£0.11 each. These issues were all in respect of the conversion of
loan notes by EHGOSF. The Company also issued 83,256 Ordinary
shares at par, to creditors as part of the CVA
arrangement.
In October 2023, the Company
issued 1,508,110 Ordinary shares of £0.10 each at par, in respect
of the conversion of £130,000 loan notes by EHGOSF, and related
conversion fees.
In November 2023, the Company
issued 1,022,490 Ordinary shares of £0.10 each at par, in respect
of the conversion of £50,000 loan notes by EHGOSF, and related
conversion fees. Also in November 2023, the Company issued 769,043
Ordinary shares of £0.10 each at par, in respect of the conversion
of £35,000 loan notes by Arch Capital Partners LLP, and related
conversion fees.
In December 2023, the Company
issued 1,495,720 Ordinary shares of £0.10 each at par, in respect
of the conversion of £70,000 loan notes by EHGOSF, and related
conversion fees.
In February 2024, the company
issued 854,700 Ordinary shares of £0.10 each at par, in respect of
the conversion of £20,000 loan notes by EHGOSF, and related
conversion fees.
At 30 June 2024, the Company had
11,161,483 Ordinary shares of £0.10 in issue and 1,637,129,905
Deferred shares of £0.00249 in issue.
In accordance with the Companies
Act 2006, the Company has no limit on its authorised share
capital.
The holders of Ordinary shares
have full voting, dividend and capital distribution rights. The
Ordinary shares do not confer any rights of redemption.
On or following the occurrence of
a change of control the receipts from the acquirer shall be applied
to the holders of the Ordinary shares pro rata to their respective
holdings.
Ordinary shares and Deferred
Shares are recorded as equity.
At 30 June 2024 the Company had
issued 11,125,000,000 (2023: 6,125,000,000) warrants to EHGOSF at a
strike price of £0.00003 (2023: £0.00003) per share. All warrants
remain outstanding at the year-end date.
12. Reserves
The following describes the nature
and purpose of each reserve within equity:
Reserve
|
Description and
purpose
|
Share premium
|
Amount
subscribed for share capital in excess of nominal value
|
Accumulated losses
|
All
other net gains and losses and transactions with owners (e.g.
dividends) not recognised elsewhere
|
13. Trade and other
payables
Group
|
|
30 June
2024
£
|
30 June
2023
£
|
Trade payables
|
|
135,289
|
1,704,142
|
Accruals
|
|
75,315
|
45,999
|
Total
|
|
210,604
|
1,750,141
|
|
|
|
|
Book values approximate to fair
values at 30 June 2024 and 30 June 2023.
|
Company
|
|
30 June
2024
£
|
30 June
2023
£
|
Trade payables
|
|
135,289
|
1,704,142
|
Accruals
|
|
75,315
|
45,999
|
|
|
210,604
|
1,750,141
|
Book values approximate to fair
values at 30 June 2024 and 30 June 2023.
14. Loans and
borrowings
Group
Current
|
|
30 June
2024
£
|
30 June
2023
(restated)
£
|
Promissory notes
|
|
631,779
|
-
|
Convertible loans
|
|
2,015,000
|
2,150,000
|
Total
|
|
2,646,779
|
2,150,000
|
Book values approximate to fair
values at 30 June 2024 and 30 June 2023.
During the current year, the
Company issued promissory notes of £325,460 to EHGOSF to provide
working capital. In addition, the Company issued a further
£306,319 of promissory notes to allow it to progress the legal and
financial due diligence to enable the RTO to proceed.
During the prior year, the Company
entered into a financing facility with EHGOSF for the issue of up
to £3m of further convertible loan notes. At the year end the
Company had drawn down £1,480,000 of the facility of which £930,000
had been converted into shares and fees of £260,000 had been
deducted. This facility is unsecured.
Company
Current
|
|
30 June
2024
£
|
30 June
2023
(restated)
£
|
Promissory notes
|
|
631,779
|
-
|
Convertible loans
|
|
2,015,000
|
2,150,000
|
Total
|
|
2,646,779
|
2,150,000
|
15. Financial Instruments
- Risk Management
The Group is exposed through its
operations to the following financial risks:
· Credit risk
· Market risk
· Liquidity risk
In common with other businesses,
the Group is exposed to risks that arise from use of financial
instruments. This note describes the group's objectives, policies
and processes for managing those risks and the methods used to
measure them.
The principal financial
instruments used by the Group, from which the financial instrument
risks arise, are as follows:
· Cash
and cash equivalents
· Trade and other receivables
· Trade and other payables
· Loans and borrowings
A summary of the financial
instruments held by category is provided below:
· Financial assets - amortised cost
· Financial liabilities - amortised cost
The contractual maturities for all
financial instruments held by the company are shown in the table
below. The table shows undiscounted principal and interest cash
flows and includes contractual gross cash flows and the net debt
reconciliation:
|
Carrying
value
|
Falling due within 1
year
|
Falling due in more than 1
year but not more than 5 years
|
Total
|
|
£
|
£
|
£
|
£
|
2024
|
|
|
Financial liabilities: current and
non-current
|
|
|
Trade and other
payables
|
210,604
|
210,604
|
-
|
210,604
|
Promissory notes
|
631,779
|
631,779
|
|
631,779
|
Convertible loan notes
|
2,015,000
|
2,015,000
|
-
|
2,015,000
|
Total financial liabilities
|
2,857,383
|
2,857,383
|
-
|
2,857,383
|
|
|
|
Financial assets: current and non-current
|
|
|
Trade and other
receivables
|
10,030
|
10,030
|
-
|
10,030
|
Cash and cash
equivalents
|
129,309
|
129,309
|
-
|
129,309
|
Total financial assets
|
139,339
|
139,339
|
-
|
139,339
|
|
|
|
|
|
Net debt
|
(2,718,044)
|
(2,718,044)
|
-
|
(2,718,044)
|
2023 (restated)
|
|
|
|
Carrying value
|
Falling due within 1 year
|
Falling due in more than 1 year but not more than 5
years
|
Total
|
Financial liabilities: current and
non-current
|
|
|
Trade and other
payables
|
1,750,141
|
1,750,141
|
-
|
1,750,141
|
Convertible loan notes
|
2,150,000
|
2,150,000
|
-
|
2,150,000
|
Other loans
|
-
|
-
|
-
|
-
|
Total financial liabilities
|
3,900,141
|
3,900,141
|
-
|
3,900,141
|
|
|
|
Financial assets: current and non-current
|
|
|
Trade and other
receivables
|
-
|
-
|
-
|
-
|
Cash and cash
equivalents
|
50,243
|
50,243
|
-
|
50,243
|
Total financial assets
|
50,243
|
50,243
|
-
|
50,243
|
|
|
|
|
|
Net debt
|
(3,849,898)
|
(3,849,898)
|
-
|
(3,849,898)
|
|
|
|
|
|
|
|
Financial assets and financial liabilities have been analysed
by category below:
|
Carrying
value
|
Financial assets at fair
value through profit or loss
|
Financial assets at fair
value through other comprehensive income
|
Liability at amortised
cost
|
Financial asset at amortised
cost
|
Fair value hierarchy
level
|
|
£
|
£
|
£
|
£
|
£
|
|
Financial assets
|
|
|
|
|
|
|
Trade & other
receivables
|
10,030
|
-
|
-
|
-
|
10,030
|
Level
2
|
Cash & cash
equivalents
|
129,309
|
-
|
-
|
-
|
129,309
|
Level
1
|
|
|
|
|
|
|
|
Financial liabilities
|
|
|
|
|
|
|
Promissory notes
|
631,779
|
-
|
-
|
631,779
|
-
|
Level
2
|
Convertible loan notes
|
2,015,000
|
-
|
-
|
2,015,000
|
-
|
Level
2
|
Trade & other
payables
|
210,604
|
-
|
-
|
210,604
|
-
|
Level
2
|
Level 1 - Fair value determined by
reference to prices in active markets for identical
assets/liabilities
Level 2 - Fair value determined by
reference to internal model with observable inputs
Group:
|
2024
£
|
2023
£
|
Cash and cash
equivalents
|
129,309
|
50,243
|
Trade and other
receivables
|
10,030
|
-
|
Total financial assets - amortised cost
|
139,339
|
50,243
|
|
2024
£
|
2023
(restated)
£
|
Trade and other
payables
|
210,604
|
1,750,141
|
Loans and borrowings
|
2,646,779
|
2,150,000
|
Total liabilities - amortised cost
|
2,857,383
|
3,900,141
|
Company:
|
2024
£
|
2023
£
|
Cash and cash
equivalents
|
129,309
|
50,243
|
Trade and other
receivables
|
10,030
|
-
|
Total financial assets - amortised cost
|
139,339
|
50,243
|
|
2024
£
|
2023
(restated)
£
|
Trade and other
payables
|
210,604
|
1,750,141
|
Loans and borrowings
|
2,646,779
|
2,150,000
|
Total liabilities - amortised cost
|
2,857,383
|
3,900,141
|
The Board has overall
responsibility for the determination of the Group's risk management
objectives and policies.
The overall objective of the Board
is to set policies that seek to reduce risk as far as possible
without unduly affecting the Groups' competitiveness and
flexibility. Further details regarding these policies are set out
below:
Credit risk
The Group applies the simplified
approach when measuring expected credit losses. The approach uses a
lifetime expected loss allowance. The expected loss rates are
reviewed annually, or when there is a significant change in
external factors potentially impacting credit risk and are updated
where management's expectations of credit losses change. No changes
have been made to the expected loss rates during the financial
year.
Financial assets held as at
year-end are as shown below (2023: £nil):
As at 31 March
2024
|
Current
£
|
More than 1 year
overdue
£
|
Total
£
|
Prepayments and accrued
income
|
10,030
|
-
|
-
|
Gross carrying amount
|
10,030
|
-
|
10,030
|
Credit risk
(Continued)
No expected credit losses have
been provided against the financial assets in the current year and
prior year.
Credit risk is the risk of
financial loss to the Group if a counterparty to the financial
instrument fails to meet its contractual obligations. It is Group
policy to assess the credit risk of new customers before entering
into contracts.
Credit risk also arises from cash
and cash equivalents and deposits with banks and financial
institutions. For banks and financial institutions, only
independently rated parties with high credit status are
accepted.
The Group does not enter into
derivatives to manage credit risk.
Group
|
2024
£
|
2023
£
|
Trade and other
receivables
|
10,030
|
-
|
Cash held at Wise Payments
Limited
|
129,309
|
50,243
|
Total financial assets
|
139,339
|
50,243
|
Company
|
2024
£
|
2023
£
|
Trade and other
receivables
|
10,030
|
-
|
Cash held at Wise Payments
Limited
|
129,309
|
50,243
|
Total financial assets
|
139,339
|
50,243
|
Market risk
Foreign exchange
risk
Foreign exchange risk arises
because the Group has operations in Portugal and Spain, whose
functional currency is not the same as the functional currency of
the Group. The Group's net assets arising from such overseas
operations are exposed to currency risk resulting in gains or
losses on retranslation into sterling.
As of 30 June 2024, the Group's
exposure to foreign exchange risk was not material as the overseas
operations had been discontinued.
Liquidity risk
Liquidity risk arises from the
Group's management of working capital. It is the risk that the
Group will encounter difficulty in meeting its financial
obligations as they fall due.
The Board will continue to monitor
long term cash projections and will consider raising funds as
required.
The following table sets out the
contractual maturities (representing undiscounted contractual
cash-flows) of financial liabilities:
Group:
2024
|
Up to
3 months
£
|
Between
3 and
12
months
£
|
Between
1 and 2
years
£
|
Between
2 and 5
years
£
|
Over 5
years
£
|
Total
£
|
|
Trade and other
payables
|
210,604
|
-
|
-
|
-
|
-
|
210,604
|
Borrowings
|
2,646,779
|
-
|
-
|
-
|
-
|
2,646,779
|
|
Total
|
2,857,383
|
-
|
-
|
-
|
-
|
2,857,383
|
|
|
|
|
|
|
|
|
|
|
2023 (restated)
|
Up to
3 months
£
|
Between
3 and
12
months
£
|
Between
1 and 2
years
£
|
Between
2 and 5
years
£
|
Over 5
years
£
|
Total
£
|
Trade and other
payables
|
1,750,141
|
-
|
-
|
-
|
-
|
1,750,141
|
Borrowings
|
2,150,000
|
-
|
-
|
-
|
-
|
2,150,000
|
Total
|
3,900,141
|
-
|
-
|
-
|
-
|
3,900,141
|
More details in regard to the line
items are included in the respective notes:
· Trade and other payables - note 13
· Loan
and borrowings - note 14
At the balance sheet date, the
Group had liabilities due for settlement within 3 months of
£2,857,383, compared to a cash balance of £129,309.
£2,015,000 of borrowings re
convertible loan notes and £631,779 of promissory notes which are
to be settled by way of an issue of share capital.
The Group monitors capital which
comprises all components of equity (i.e. share capital, share
premium and accumulated deficit).
The directors are aware of the
need for the Group to obtain capital in order to fund the growth of
the business and are in continual discussions with providers of
both debt and equity capital. The directors regularly review the
status of such discussions and aim at all times to have offers of
capital funding available to the Company which more than exceed the
needs of the Company over the coming period.
In the medium term and in addition
to the need to safeguard the entity's ability to continue as a
going concern, the directors are aware of the views of members on
certain financing structures and therefore have set an objective to
move towards a conventional, simplified capital structure based on
equity capital.
Further details about the
directors' assessment of the Group's ability to continue as a going
concern and the key considerations there to are set out in the
Corporate Governance Report.
At present the directors do not
intend to pay dividends but will reconsider the position in future
periods, as the Group becomes profitable.
16. Prior period
adjustment
During the preparation of these
financial statements, the Group identified an error where fees
incurred on the draw down of convertible loan notes were omitted
from the accounting records and financial statements in the prior
year. As a result of this error, convertible loan notes, reported
within loans and borrowings in the Consolidated Statement of
Financial Position, were understated by £210,000. Legal and waiver
fees reported within administrative expenses in the Consolidated
Statement of Comprehensive Income were also understated by
£210,000.
The table below summarises the
effect of the correction of the prior period error on the financial
statement.
Impact on Consolidated Statement of Financial
Position
As at 30 June 2023
|
As previously
reported
|
Adjustment to correct
error
|
Restated
balance
|
|
£
|
£
|
£
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Loans and borrowings
|
(1,940,000)
|
(210,000)
|
(2,150,000)
|
|
|
|
|
Equity
|
|
|
|
Accumulated losses
|
(16,521,181)
|
(210,000)
|
(16,731,181)
|
Impact on Consolidated Statement of Profit or Loss and Other
Comprehensive Income
For the year ended 30 June 2023
|
As previously
reported
|
Adjustment to correct
error
|
Restated
balance
|
|
£
|
£
|
£
|
Administration expenses
|
4,768,579
|
(210,000)
|
4,558,579
|
Profit before taxation
|
4,768,579
|
(210,000)
|
4,558,579
|
The above errors have been
corrected by restating the affected amounts in the prior period
financial statements, as if the errors had never occurred in
accordance with IAS 8. The restated figures are reflected in the
comparative amounts for the period ended 30 June 2023 in these
financial statements.
17. Capital
commitments
The Group had no capital
commitments at 30 June 2024 or 30 June 2023.
18. Related party
Transactions
Details of Directors' remuneration
are given in the Remuneration Committee Report.
19. Contingent
Liabilities
The Company has contingent
liabilities amounting to £255,000 that are payable to advisors upon
completion of the reverse takeover and re-admission to trading.
Should the reverse takeover not be successful, this amount is not
payable.
The Group had no contingent
liabilities at 30 June 2023.
20.
Ultimate
Controlling Party
The Directors do not consider that
there is an ultimate controlling party of Iconic Labs
Plc.
21. Reconciliation of
movement in net (debt)/cash
|
Net debt at 01 July 2023
|
Cash flow
|
Non-cash change in loan
notes
|
Repayment of borrowings
(continuing activities)
|
Conversion of loan notes to
equity
|
Net cash
at 30 June 2024
|
|
£
|
£
|
£
|
£
|
£
|
£
|
|
|
|
|
|
|
|
Cash at bank and in hand
|
50,243
|
79,066
|
-
|
-
|
-
|
129,309
|
Borrowings
|
(2,150,000)
|
(881,779)
|
(260,000)
|
-
|
435,000
|
(2,646,779)
|
|
|
|
|
|
|
|
Total financial liabilities
|
(2,099,757)
|
(802,713)
|
(260,000)
|
-
|
435,000
|
(2,517,470)
|
|
|
|
|
|
|
|
|
Net debt at 01 July 2022
|
Cash flow
|
Non-cash change in loan
notes
|
Repayment of borrowings
(continuing activities)
|
Conversion of loan notes to
equity
|
Net cash
at 30 June 2023
|
|
|
|
(restated)
|
|
|
(restated)
|
|
£
|
£
|
£
|
£
|
£
|
£
|
|
|
|
|
|
|
|
Cash at bank and in hand
|
5
|
50,238
|
-
|
-
|
-
|
50,243
|
Borrowings
|
(2,415,000)
|
(970,000)
|
705,000
|
-
|
530,000
|
(2,150,000)
|
|
|
|
|
|
|
|
Total financial liabilities
|
(2,414,995)
|
(919,762)
|
705,000
|
-
|
530,000
|
(2,099,757)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22. Subsequent Events
On 29 July 2024, the Listing Rules
were replaced by the UK Listing Rules ("UKLR") under which the
existing Standard Listing category was replaced by the Equity
Shares (shell companies) category under Chapter 13 of the UKLR as
it applied to the Company. Consequently, with effect from
that date the Company is admitted to Equity Shares (shell
companies) category of the Official List under Chapter 13 of the
UKLR and to trading on the London Stock Exchange's Main Market for
listed securities.